Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENTHUSE M0: Zibotentan in Non-Metastatic HRPC
NCT00626548Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Jan 2008
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 39
01
Overview
A Phase 3 trial of zibotentan in prostate cancer (PCa), sponsored by AstraZeneca. Started Jan 2008; status: terminated.
02
Drugs
zibotentan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00626548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00626548.